The company's engineered bacterial therapies focus on healthy gut bacteria and their predatory phages to engineer resistant strains, allowing medical professionals to specifically target viruses that induce lysis of certain bacterial cells. Ancilia's approach harnesses the natural function of CRISPR to enhance bacterial immunity against viruses and modulate the human microbiome, with a focus on treating chronic diseases across immunology and oncology indications.